Dec 14, 2023 | News

Qinecsa appoints John Freeman JD, M.Sc., B.Sc. to the Board of Directors

Announcement – 14th December 2023, London – Qinecsa Solutions, specialists in technology-led end-to-end pharmacovigilance solutions, today announced the appointment of John Freeman JD, M.Sc., B.Sc. as Non-executive Director.

With a background in Clinical Pharmacology and Law, John has held prominent global leadership roles in pharmacovigilance and risk management. He has worked in the field of pharmacovigilance since 1986. Initially based in Europe he spent 5 years working within Glaxo’s Safety Surveillance Department where he was responsible for the safety surveillance of respiratory products.

Subsequently, John spent 10 years in the UK as Amgen’s first EU Qualified Person for Pharmacovigilance where he built and headed Amgen’s European pharmacovigilance program. More latterly he was based within Amgen’s headquarters office in California where he was responsible for global pharmacovigilance operations.

Between 2005 and 2019, John built and lead Celgene’s Global Drug Safety and Risk Management division. In this time he successfully oversaw the global expansion of Celgene’s product approvals and infrastructure to more than 80 markets including the world’s most rigorous risk management programs for thalidomide and its analogues.

Most recently John was the Chief Safety Officer for BeiGene where he established a comprehensive pre- and post-market pharmacovigilance program with hubs in China and the USA.

Throughout his time in industry John has delivered against the target of pharmacovigilance as a value driver beyond compliance to include meaningful strategic support to both clinical development and commercialization.

“Qinecsa has an exciting vision to facilitate real change in Pharmacovigilance.  I’m delighted to be a part of that journey, leveraging my expertise to drive the future direction of Qinecsa, and guide it towards unprecedented growth and innovation for the benefit of patients and the pharmaceutical industry as a whole,” said John Freeman.

“We are honored to welcome John to our board of directors,” commented John Gillie, CEO of Qinecsa Solutions. “As a distinguished leader with extensive experience in global pharmacovigilance, unparalleled knowledge, and visionary leadership will chart new heights for our journey in advancing technology-driven pharmacovigilance solutions.”



About Qinecsa Solutions 

Qinecsa specializes in technology-led end-to-end pharmacovigilance solutions. We are trusted, global partners bringing together best-in-class technology and scientific expertise to connect life science companies to the right safety solutions. Through our unique insight into the challenges of pharmacovigilance, we have created industry-leading, end-to-end solutions for capturing, managing, and evaluating drug safety data, more efficiently and accurately. Working with life science companies we drive progress to continue protecting lives.

For inquiries: contact@qinecsa.com

Resources

Join Qinecsa at DIA Europe 2024

Join Qinecsa at DIA Europe 2024

Qinecsa is excited to be exhibiting for the first time at the DIA Europe regional annual meeting from 12-14 March at the SQUARE Brussels Meeting Centre in Brussels, Belgium. DIA Europe 2024 will focus on sustainability, innovation and collaboration – three key pillars...

Qinecsa company brochure

Qinecsa company brochure

Qinecsa specializes in technology-led, end-to-end pharmacovigilance solutions, built on over 17 years of heritage expertise. As a trusted global partner, we combine best-in-class technology with scientific know-how to connect life science companies with the right...

Reportum pharmacovigilance platform

Reportum pharmacovigilance platform

Reportum is a unified adverse event platform managing both digital and analogue intake from all sources. It offers a digital-first experience for consumers and healthcare professionals, as well as expert pharma users in call centers, PSPs, sales organizations and...